DDInter94 DDInter298
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Isradipine {u} (Compound) downregulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cladribine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds SOD1 (Gene) and SOD1 (Gene) is bound by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds SLC31A1 (Gene) and Bortezomib (Compound) upregulates SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Carboplatin (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) downregulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Carboplatin (Compound)